Prediction of Maternal and Fetoplacental Concentrations of Cefazolin, Cefuroxime, and Amoxicillin during Pregnancy Using Bottom-Up Physiologically Based Pharmacokinetic Models
- PMID: 35046066
- DOI: 10.1124/dmd.121.000711
Prediction of Maternal and Fetoplacental Concentrations of Cefazolin, Cefuroxime, and Amoxicillin during Pregnancy Using Bottom-Up Physiologically Based Pharmacokinetic Models
Abstract
Concerns over maternal and fetal drug exposures highlight the need for a better understanding of drug distribution into the fetus through the placental barrier. This study aimed to predict maternal and fetal drug disposition using physiologically based pharmacokinetic (PBPK) modeling. The detailed maternal-placental-fetal PBPK model within the Simcyp Simulator V20 was used to predict the maternal and fetoplacental exposure of cefazolin, cefuroxime, and amoxicillin during pregnancy and at delivery. The mechanistic dynamic model includes physiologic changes of the maternal, fetal, and placental parameters over the course of pregnancy. Placental kinetics were parametrized using permeability parameters determined from the physicochemical properties of these compounds. Then, the PBPK predictions were compared with the observed data. Fully bottom-up fetoplacental PBPK models were developed for cefuroxime, cefazolin, and amoxicillin without any parameter fitting. Predictions in nonpregnant subjects and in pregnant subjects fall within 2-fold of the observed values. Predictions matched observed pharmacokinetic data reported in nine maternal (five fetoplacental) studies for cefuroxime, 10 maternal (five fetoplacental) studies for cefazolin, and six maternal (two fetoplacental) studies for amoxicillin. Integration of the fetal and maternal system parameters within PBPK models, together with compound-related parameters used to calculate placental permeability, facilitates and extends the applications of the maternal-placental-fetal PBPK model. The developed model can also be used for designing clinical trials and prospectively used for maternal-fetal risk assessment after maternally administered drugs or unintended exposure to environmental toxicants. SIGNIFICANCE STATEMENT: This study investigates the performance of an integrated maternal-placental-fetal PBPK model to predict maternal and fetal tissue exposure of renally eliminated antibiotics that cross the placenta through a passive diffusion mechanism. The transplacental permeability clearance was predicted from the drug physicochemical properties. Results demonstrate that the PBPK approach can facilitate the prediction of maternal and fetal drug exposure simultaneously at any gestational age to support its use in the maternal-fetal exposure assessments.
Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.
Similar articles
-
Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.Clin Pharmacokinet. 2022 May;61(5):725-748. doi: 10.1007/s40262-021-01103-0. Epub 2022 Jan 24. Clin Pharmacokinet. 2022. PMID: 35067869
-
Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.Clin Pharmacokinet. 2017 Dec;56(12):1525-1541. doi: 10.1007/s40262-017-0538-0. Clin Pharmacokinet. 2017. PMID: 28391404
-
Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.Drug Metab Dispos. 2017 Aug;45(8):939-946. doi: 10.1124/dmd.116.073957. Epub 2017 Jan 3. Drug Metab Dispos. 2017. PMID: 28049636 Free PMC article.
-
Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.J Clin Pharmacol. 2022 Sep;62 Suppl 1(Suppl 1):S94-S114. doi: 10.1002/jcph.2117. J Clin Pharmacol. 2022. PMID: 36106781 Free PMC article. Review.
-
A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome.Pharmacol Ther. 2022 Jun;234:108045. doi: 10.1016/j.pharmthera.2021.108045. Epub 2021 Nov 20. Pharmacol Ther. 2022. PMID: 34813863 Review.
Cited by
-
Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime.Clin Pharmacokinet. 2024 Jan;63(1):69-78. doi: 10.1007/s40262-023-01323-6. Epub 2023 Nov 14. Clin Pharmacokinet. 2024. PMID: 37962827
-
The Impact of Inflammation on the In Vivo Activity of the Renal Transporters OAT1/3 in Pregnant Women Diagnosed with Acute Pyelonephritis.Pharmaceutics. 2023 Oct 5;15(10):2427. doi: 10.3390/pharmaceutics15102427. Pharmaceutics. 2023. PMID: 37896187 Free PMC article.
-
An update on placental drug transport and its relevance to fetal drug exposure.Med Rev (2021). 2022 Nov 21;2(5):501-511. doi: 10.1515/mr-2022-0025. eCollection 2022 Oct. Med Rev (2021). 2022. PMID: 37724167 Free PMC article. Review.
-
Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure.Front Pharmacol. 2023 Mar 23;14:1111601. doi: 10.3389/fphar.2023.1111601. eCollection 2023. Front Pharmacol. 2023. PMID: 37033628 Free PMC article. Review.
-
PBPK-based dose finding for sildenafil in pregnant women for antenatal treatment of congenital diaphragmatic hernia.Front Pharmacol. 2023 Mar 14;14:1068153. doi: 10.3389/fphar.2023.1068153. eCollection 2023. Front Pharmacol. 2023. PMID: 36998614 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical